targetting pd-l1 with avelumab in metastatic merkel cell carcinoma
Published 8 years ago • 1.3K plays • Length 5:55Download video MP4
Download video MP3
Similar videos
-
2:18
durable responses to avelumab in patients with merkel cell carcinoma
-
1:36
avelumab and pembrolizumab for the treatment of merkel cell carcinoma
-
1:37
avelumab for treatment of metastatic merkel cell carcinoma
-
1:06
managing avelumab side effects in patients with merkel cell carcinoma
-
6:38
efficacy of pd-l1 inhibitor avelumab in nepc/avpc
-
1:08
dr. kaufman on avelumab in merkel cell carcinoma
-
2:11
using immuno-oncology agents in merkel cell carcinoma
-
2:03
avelumab in merkel cell carcinoma – updates from asco 2017
-
1:18
dr. nghiem on challenges with immunotherapy in merkel cell carcinoma
-
7:11
avelumab in combinations for lung cancer and update from alex study
-
1:03
role of immunotherapy in merkel cell carcinoma
-
2:24
exploring the impact of anti-pd-1 and anti-pd-l1 agents in merkel cell carcinoma
-
1:38
dr. lebbe discusses efficacy of avelumab in merkel cell carcinoma
-
0:46
immune checkpoint inhibitors: recent progress and potential biomarkers - 3iv pd-l1 overexpression
-
1:09
new standard of care for merkel cell carcinoma
-
4:31
treatment updates in merkel cell carcinoma
-
2:38
long-term follow-up results from javelin merkel 200 and keynote-017 in mcc
-
0:50
pd-1 and pd-l1 receptors: key players in immunotherapy 🎗️🔬
-
3:59
the selection of pd-l1 escape variants in microsatellite stable metastatic crc on avelumab treatment